Overview

Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)

Status:
Completed

Trial end date:
2017-12-05

Target enrollment:

Participant gender:

Summary

The purpose of this study was to assess the efficacy and safety of the anti-Vascular Endothelial Growth Factor (VEGF) agent ranibizumab (0.5 mg) with or without Panretinal laser photocoagulation (PRP) compared to PRP alone in patients with Proliferative Diabetic Retinopathy (PDR).

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Collaborators:

Cologne Image Reading Center & Laboratory (CIRCL)
Spranger Laboratories

Treatments:

Ranibizumab